Breaking
new ground

in immuno-oncology

Breaking
new ground

in immuno-oncology

Immunocore

Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology, which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases.

panel-1.jpg

Discovery and
validation of novel
disease targets
 

Learn more

panel-2.jpg

ImmTACs – redefining
immuno-oncology
through TCR targeted
T cell redirection

Learn more

panel-3.jpg

ImmTACs in the
clinic – delivering
better tomorrows
 

Learn more